Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINIST: Safety of Alpelisib Plus Fulvestrant in HR+, HER2-, PIK3CA-mutated Advanced Breast Cancer
NCT05631795Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of alpelisib in breast cancer, sponsored by Novartis. Started Aug 2022; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05631795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631795.